

Vyvgart Hytrulo[®] (efgartigimod alfa/hyaluronidase-qvfc) – New dosage form approval

- On April 10, 2025, [argenx announced](#) the FDA approval of **self-injectable prefilled syringe version of Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc)**, for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and chronic inflammatory demyelinating polyneuropathy (CIDP).
- The new dosage form contains 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase per 5 mL (200 mg/2,000 units per mL) in a single-dose prefilled syringe.
- **Vyvgart Hytrulo was previously approved as a single-dose vial** containing 1,008 mg efgartigimod alfa and 11,200 units hyaluronidase per 5.6 mL (180 mg/2,000 units per mL).
 - The vial required administration by a healthcare professional.
- The recommended dose of Vyvgart Hytrulo prefilled syringe for gMG is 1,000 mg / 10,000 units administered subcutaneously over approximately 20 to 30 seconds in cycles of once weekly injections for 4 weeks.
- The recommended dose of Vyvgart Hytrulo prefilled syringe for CIDP is 1,000 mg / 10,000 units administered subcutaneously over approximately 20 to 30 seconds as once weekly injections.
- Refer to the Vyvgart Hytrulo drug label for dosing for the single-dose vial.
- Argenx's launch plans for Vyvgart Hytrulo prefilled syringe are pending.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.